Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Patients Following Ablation of Atrial Fibrillation

Jeong-Hwan Park, MD, Yong-Seog Oh, MD, Ji-Hoon Kim, MD, Woo-Baek Chung, MD, Su-Sung Oh, MD,
Dong-Hyun Lee, MD, Yun-Seok Choi, MD, Woo-Seung Shin, MD, Chul-Soo Park, MD,
Ho-Joong Youn, MD, Wook-Sung Chung, MD, Man-Young Lee, MD, Ki-Bae Seung, MD,
Tae-Ho Rho, MD, Jae-Hyung Kim, MD and Soon-Jo Hong, MD

Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

ABSTRACT

Background and Objectives: It is known that angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers (ACEIs and ARBs, respectively) are effective in preventing atrial fibrillation (AF) in high-risk patients. However, it is not known whether ACEIs and ARBs are effective in preventing the recurrence of AF after catheter ablation. **Subjects and Methods**: One hundred fifty-two patients (mean age, 57 ± 10 years; M : F=94 : 58) who underwent catheter ablation due to drug-refractory paroxysmal (mean age, 57 ± 10 years; M : F=58 : 43) or persistent AF (mean age, 56 ± 10 years; M : F=36 : 15) were enrolled. We compared the recurrence rates between the groups with and without ACEIs or ARBs use in paroxysmal and persistent AF. The mean duration of follow-up was 18 ± 14 months. **Results**: The overall recurrence rate after ablation therapy was 26% (n=39). The recurrence rate was significantly decreased in the patients with persistent AF with the use of ACEIs or ARBs (12.1% vs. 61.1%, p<0.01), but this difference was not observed in the patients with paroxysmal AF (24.2% vs. 22.9%, p= 0.87). In patients with persistent AF with and without recurrence, the size of the left atrium (44.2 ± 8.4 mm vs. 44.3 ± 5.8 mm, respectively, p=0.45) and the ejection fraction (62 ± 6.5% vs. 61.5 ± 6.2%, respectively, p=0.28) were not significantly different. In multivariate analysis, the use of ACEIs or ARBs was independently associated with recurrence after adjusting for the size of the left atrium and the ejection fraction {odds ratio (OR)=0.078, 95% confidence interval (CI)=0.02-0.35, p<0.01}. **Conclusion**: ACEIs and ARBs were shown to be effective in preventing AF recurrence after catheter ablation in patients with persistent AF. **(Korean Circ J 2009;39:185-189)**

KEY WORDS: Atrial fibrillation; Catheter ablation; Angiotensin-converting enzyme inhibitors; Angiotensin II type 1 receptor blockers.

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of substantial mortality and morbidity from stroke, thromboembolism, and heart failure, leading to an impaired quality of life.[1-5] With the increase of elderly population in the developed world, the prevalence of AF is increasing, resulting in a major public health problem.[6] Maintenance of sinus rhythm is the main therapeutic goal in patients with AF.

Radiofrequency catheter ablation (RFCA) for AF has been proposed as an effective therapeutic option for AF that is resistant to pharmacologic rhythm or rate control, with successful long-term maintenance of sinus rhythm in the absence of treatment with anti-arrhythmic drugs reported in the majority of patients.[7] However, the recurrence of AF after RFCA is not uncommon. The recurrence rate of AF after RFCA has been reported to be between 30 and 40%, depending on the ablation strategy and the type of AF.[7-10] Some investigators have reported that the left atrial diameter/volume and hypertension are predictors of AF recurrence after RFCA.[11]12]

Recent research has focused increasingly on atrial structural remodeling and electrical dysfunction, which

underlie the development of AF in different pathologic conditions.[13-17] A particular interest has been generated in the role of renin-angiotensin system (RAS) blockade in reversing the electrical and structural remodeling of diseased atria.

Angiotensin-converting enzyme inhibitors (ACEIs) are known to suppress structural and functional remodeling and prevent the induction and promotion of AF in chronic rapid atrial pacing dogs.[18] In several animal models, it has been suggested that angiotension II type 1 receptor blockers (ARBs) might be useful for preventing AF recurrence after the termination of sustained AF by decreasing interstitial fibrosis.[19][20] However, there is still uncertainty about the role of ACEIs and ARBs for the reduction of AF recurrence after RFCA in clinical practice.

This study was aimed to evaluate the effect of ACEIs and ARBs on the recurrence of AF after RFCA.

Subjects and Methods

We retrospectively evaluated 152 patients (mean age, 57 ± 10 years; M : F=94 : 58) who underwent AF ablation due to drug-refractory paroxysmal (mean age, 57 ± 10 years; M : F=58 : 43) or persistent AF (mean age, 56 ± 10 years; M : F=36 : 15).

Among the 152 patients, 101 had paroxysmal AF (PAF) and 51 had persistent AF (PeAF). PAF was defined as the occurrence of two or more episodes of AF during the previous 12 months, typically lasting <7 days and terminating spontaneously. PeAF was defined as the occurrence of AF episodes lasting <7 days, and typically requiring cardioversion for restoration of normal sinus rhythm. The AF ablation strategy was 3D mapping (CARTO)-guided circumferential ablation, pulmonary vein ostial ablation, and roof line, mitral valve isthmus, and right cavotricuspid isthmus block. AF ablation techniques were identical for all patients.

After discharge, the patients were followed 1-2 weeks later, and then visited our hospital every 1-3 months during the first year after RFCA. Whenever the patients visited our clinic, a history was taken and a physical examination was performed. Additionally, a 12-lead electrocardiography (ECG) and 24-hour ambulatory Holter ECG monitoring (24 hours Holter monitoring) were obtained. Thereafter, we immediately checked a 12-lead ECG and 24 hours Holter monitoring if the patients complained of symptoms, such as palpitations that suggest AF. Twenty-four hours Holter monitoring was also performed on asymptomatic patients every 6 months.

Recurrence was defined if the patients showed AF on a 12-lead ECG and/or on 24 hours Holter monitoring, or complained of typical episodes of palpitation sat the 3-month follow-up visit after RFCA.

We compared the recurrence rates between the PAF

and PeAF groups that received ACEIs or ARBs. ACEIs or ARBs were prescribed at least 1 month prior to ablation and for the duration of the follow-up. We used the standard doses that are generally recommended for ACEIs or ARBs. The mean follow-up duration was 18 ± 14 months.

Statistical analysis

The Statistical Package for Social Sciences (SPSS) for Windows, version 15.0 (Chicago, IL, USA) was used for all analyses. The continuous variables are presented as the mean values $\pm$ standard deviations (SDs) and were compared using paired or unpaired Student's t-tests. A $p<0.05$ was considered statistically significant.

Results

The PAF and PeAF groups, with or without ACEIs or ARBs, were similar with respect to important baseline clinical characteristics (Table 1 and 2). Furthermore, there was no difference in medications, including antiarrhythmic drugs other than ACEIs/ARBs for the PAF and PeAFgroups (Table 3 and 4).

The overall recurrence rate after ablation therapy was 26% (n=39). In PAF patients, no significant differences existed in the recurrence rates between the group with ACEIs or ARBs and the group without ACEIs or ARBs (24.2% vs. 22.9%, p=0.87) (Fig. 1). However, in PeAF patients, compared with the group not using ACEIs or ARBs, the recurrence rate was significantly decreased in the group using ACEIs or ARBs (12.1% vs.

Table 1. Baseline clinical characteristics of the PAF patients

	PAF+A (n=66)	PAF-A (n=35)	p
Age (years)	57.9 ± 10	56.8 ± 11	0.62
Male, n (%)	39 (59.0)	19 (54.2)	0.36
LA dimension (mm)	38.8 ± 5	38.5 ± 5	0.78
LVEF (%)	63.1 ± 7	62 ± 7	0.44
AF duration (months)	34 ± 23	33 ± 28	0.52
Diabetes, n (%)	7 (10.6)	4 (11.4)	0.90
Hypertension, n (%)	18 (27.2)	9 (25.7)	0.86
COPD, n (%)	1 (1.5)	2 (5.7)	0.23
CKD, n (%)	1 (1.5)	1 (2.8)	0.64
CAD, n (%)	5 (7.5)	2 (5.7)	0.72
LVH, n (%)	8 (12.1)	3 (8.5)	0.58
Mitral stenosis, n (%)	3 (4.5)	2 (5.7)	0.79
CRP (mg/L)	2.40 ± 0.9	2.22 ± 1.19	0.39
Pro-BNP (pg/mL)	63 ± 26	55 ± 19	0.12

Values are expressed as the means $\pm$ SD. PAF+A: paroxysmal atrial fibrillation with ACEIs or ARBs, PAF-A: paroxysmal atrial fibrillation wihout ACEIs or ARBs, LA: left atrium, LVEF: left ventricle ejection fraction, COPD: chronic obstructive pulmonary disease, CKD: chronic kidney disease, CAD: coronary artery disease, LVH: left ventricle hypertrophy, CRP: C-reactive protein, Pro-BNP: Pro-Brain natriuretic peptide, ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin II type 1 receptor blockers

Table 2. Baseline clinical characteristics of the PeAF patients

	PeAF+A (n=33)	PeAF-A (n=18)	p
Age (years)	54.1±10	58.0±9	0.21
Male (%)	23 (69.6)	12 (66.6)	0.51
LA dimension (mm)	43.8±6	44.7±7	0.65
LVEF (%)	61.0±6	63.2±5	0.24
AF duration (months)	21±10	24±11	0.38
Diabetes, n (%)	10 (30.3)	4 (22.2)	0.53
Hypertension, n (%)	13 (39.3)	6 (33.3)	0.66
COPD, n (%)	2 (6.0)	1 (5.5)	0.94
CKD, n (%)	1 (3.0)	1 (5.5)	0.65
CAD, n (%)	3 (9.0)	1 (5.5)	0.60
LVH, n (%)	4 (12.1)	2 (11.1)	0.91
Mitral stenosis, n (%)	1 (3.0)	3 (16.6)	0.08
CRP (mg/L)	2.63±1.47	2.76±1.25	0.75
Pro-BNP (pg/mL)	98±43	88±25	0.37

Values are expressed as the means±SD. PAF+A: paroxysmal atrial fibrillation with ACEIs or ARBs, PAF-A: paroxysmal atrial fibrillation wihout ACEIs or ARBs, LA: left atrium, LVEF: left ventricle ejection fraction, COPD: chronic obstructive pulmonary disease, CKD: chronic kidney disease, CAD: coronary artery disease, LVH: left ventricle hypertrophy, CRP: C-reactive protein, Pro-BNP: Pro-brain natriuretic peptide, ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin II type 1 receptor blockers

Table 3. Medications other than ACEIs or ARBs after catheter ablation for PAF

	PAF+A (n=66)	PAF-A (n=35)	p
Sotalol, n (%)	40 (60.6)	20 (57.1)	0.73
Amiodarone, n (%)	8 (12.1)	5 (14.2)	0.75
Flecainide, n (%)	12 (18.1)	6 (17.1)	0.89
Propafenone, n (%)	6 (9.0)	4 (11.4)	0.70
Beta-blcoker, n (%)	12 (18.1)	8 (22.8)	0.37
Calcium channel blocker, n (%)	5 (7.5)	6 (17.7)	0.14
Statin, n (%)	35 (53.0)	21 (60.0)	0.32
Spironolactone, n (%)	7 (10.6)	3 (8.5)	0.74

PAF+A: paroxysmal atrial fibrillation with ACEIs or ARBs, PAF-A: paroxysmal atrial fibrillation wihout ACEIs or ARBs, ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin II type 1 receptor blockers

Table 4. Medications other than ACEIs or ARBs after catheter ablation for PeAF

	PeAF+A (n=33)	PeAF-A (n=18)	p
Sotalol, n (%)	10 (30.3)	7 (38.8)	0.53
Amiodarone, n (%)	5 (15.1)	4 (22.2)	0.52
Flecainide, n (%)	15 (45.4)	6 (33.3)	0.40
Propafenone, n (%)	3 (9.0)	1 (5.5)	0.65
Beta-blcoker , n (%)	6 (18.1)	2 (11.1)	0.50
Calcium channel blocker, n (%)	3 (9.0)	5 (27.7)	0.079
Statin, n (%)	12 (36.3)	9 (50.0)	0.34
Spironolactone, n (%)	2 (6.0)	1 (5.5)	0.94

PeAF+A: persistent atrial fibrillation with ACEIs or ARBs, PeAF-A: persistent atrial fibrillation wihout ACEIs or ARBs ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin II type 1 receptor blockers

ing etiology is probably different in different patient subpopulations. The paroxysms of AF are consistently initiated by a spontaneous firing focus arising from several sites, including the pulmonary veins,[21-24] the vein of Marshall,[25] the coronary sinus,[23][26] the crista terminalis,[23][26] the superior vena cava, and the inferior vena cava. The role of substrate is not as important as in PAF.

However, electrophysiologic remodeling is commonly observed and is probably an important factor contributing to the persistence of AF. In addition to eletrophysiologic remodeling, structural remodeling, such as fibrosis (at both the subcellular and tissue levels) is also often present and contributes to the altered tissue substrate that promotes AF maintenance.[27]

Although there are many anti-arrhythmic drugs available to maintain sinus rhythm and reduce the ventricular rate, there is no drug which can control AF effectively.

Because RFCA can effectively treat patients with drug-refractory AF, RFCA has emerged as a major treatment option for AF. However, this procedure is limited by a significant rate of AF recurrence and the effect of RFCA on patients with PeAF is not as effective as on PAF. This phenomenon may be caused by structural and electrical remodeling of the atrium during the long period of AF.

Several experimental studies have demonstrated that atrial cells express all components of RAS in a pig model of AF,[28] remodeling of the atrium correlated with a high level of angiotensin in atrial tissue, and blockade of RAS through ACEIs or ARBs can reverse atrial remodeling.[13][18][29] Nakashima et al.[30] first demonstrated the role of ACEIs and ARBs in preventing atrial electrical remodeling. They found that in dogs in which the atria were paced at 800 beats/min, candesartan and captopril prevented the atrial effective refractory period from shortening.

In the current study, the overall recurrence rate after ablation therapy was 26% (n=39). The recurrence rate was significantly decreased in the PeAF group that used ACEIs or ARBs (12.1% vs. 61.1%, p<0.01). This result

61.1%, p<0.01) (Fig. 1).

In PeAF patients with and without recurrence, the left atrium dimension (44.2±8.4 mm vs. 44.3±5.8 mm, respectively, p=0.45) and the left ventricle ejection fraction (62±6.5% vs. 61.5±6.2%, respectively, p=0.28) were not significantly different.

In multivariate analysis, the use of ACEIs or ARBs was independently associated with recurrence after adjusting for the left atrium dimension and the left ventricle ejection fraction (OR=0.078, 95% CI=0.02-0.35, p<0.01).

Discussion

AF is a complex, multifactorial disease. The underly-

Fig. 1. Comparison of recurrence rates between the persistent and paroxysmal atrial fibrillation groups with and without the use of ACEIs or ARBs. A: recurrence rate in persistent AF. B: recurrence rate in paroxysmal AF. ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin II type 1 receptor blockers.

might be caused by the effect of ACEIs or ARBs on alteration of left atrial remodeling and reduction of interstitial fibrosis through RAS blockade. However, this difference in the recurrence rate was not observed in PAF patients (24.2% vs. 22.9%, p=0.87).

We presume that the reason for this outcome might be caused by difference of pathophysiologic mechanisms between PAF and PeAF. That is to say, PAF is mainly triggered by electric foci, but electrophysiologic or structural remodeling underlie PeAF. Therefore, ACEIs or ARBs which can alter remodeling, played an important role in reducing the recurrence rate of PeAF, but not PAF.

Conclusions

ACEIs or ARBs might be effective in preventing AF recurrence after catheter ablation in PeAF patients.

Limitations of the study

This study had several limitations. First, this was a retrospective study. Second, this single-center study included only a small number of patients. Therefore, further prospective, randomized, large-scale studies are required.

REFERENCES

1) Wolf PA, Abbott RD, Kannel WB. *Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.*
2) Olsson LG, Swedberg K, Ducharme A, et al. *Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004.*
3) Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. *Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.*
4) Wang TJ, Larson MG, Levy D, et al. *Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107:2920-5.*
5) Dorian P, Jung W, Newman D, et al. *The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000;36:1303-9.*
6) Lip GY, Tse HF. *Management of atrial fibrillation. Lanset 2007; 370:604-18.*
7) Oral H, Pappone C, Chugh A, et al. *Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354:934-41.*
8) Wazni OM, Marrouche NF, Martin DO, et al. *Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation. JAMA 2005;293:2634-40.*
9) Mansour M, Ruskin J, Keane D. *Efficacy and safety of segmental ostial versus circumferential extra-ostial pulmonary vein isolation for atrial fibrillation. J Cardiovasc Electrophysiol 2004;15: 532-7.*
10) Cappato R, Calkins H, Chen SA, et al. *Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005;111:1100-5.*
11) Shin SH, Park MY, Oh WJ, et al. *Left atrial volume is a predictor of atrial fibrillation recurrence after catheter ablation. J Am Soc Echocardiogr 2008;21:697-702.*
12) Berruezo A, Tamborero D, Mont L, et al. *Pre-procedural of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 2007;28:836-41.*
13) Casaclang-Verzosa G, Gersh BJ, Tsang TS. *Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008;51:1-11.*
14) Grubitzsch H, Menes A, Modersohn D, Konertz W. *The role of atrial remodeling for ablation for atrial fibrillation. Ann Thorac Surg 2008;85:474-80.*
15) Mesas CE, Augello G, Lang CC, et al. *Electroanatomic remodeling of the left atrium in patients undergoing repeat pulmonary vein ablation: mechanistic insights and implications for ablation. J Cardiovasc Electrophysiol 2006;17:1279-85.*
16) Imada M, Funabashi N, Asano M, Uehara M, Ueda M, Komuro I. *Anatomical remodeling of left atria in subjects with chronic and paroxysmal atrial fibrillation evaluated by multislice computed tomography. Int J Cardiol 2007;119:384-8.*
17) Everett TH 4th, Wilson EE, Verheule S, Guerra JM, Foreman S, Olgin JE. *Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling. Am J Physiol Heart Circ Physiol 2006;291:H2911-23.*
18) Li Y, Li W, Yang B, et al. *Effects of cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogs. J*

Electrocardiol 2007;40:100, e1-6.

19) Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. *Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-204.*

20) Nakashima H, Kumagai K. *Reverse-remodeling effects of angiotensin II type 1 receptor blockers in a canine atrial fibrillation model. Circ J 2007;71:1977-82.*

21) Haissaguerre M, Jais P, Shah DC, et al. *Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996;7:1132-44.*

22) Haissaguerre M, Jais P, Shah DC, et al. *Spontaneous initiation of atria fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.*

23) Jais P, Haissaguerre M, Shah DC, et al. *A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997;95:572-6.*

24) Chen SA, Hsieh MH, Tai CT, et al. *Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999;100:1879-86.*

25) Hwang C, Wu TJ, Doshi RN, Peter CT, Chen PS. *Vein of marshall cannulation for the analysis of electrical activity in patients with focal atrial fibrillation. Circulation 2000;101:1503-5.*

26) Chen SA, Tai CT, Yu WC, et al. *Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation. J Cardiovasc Electrophysiol 1999;10:328-35.*

27) Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. *Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997;96:3157-63.*

28) Tsai CT, Lai LP, Hwang JJ, et al. *Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation. J Hypertens 2008;26:570-82.*

29) Shi Y, Li D, Tardif JC, Nattel S. *Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456-61.*

30) Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. *Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-7.*